Improve time to anti-coagulation reversal for hemorrhagic strokes
- PMID: 39413862
- DOI: 10.1016/j.jstrokecerebrovasdis.2024.108090
Improve time to anti-coagulation reversal for hemorrhagic strokes
Abstract
Background: Oral anticoagulation (OAC) is a risk factor for intracerebral hemorrhage (ICH) which is an important source of disability and mortality. OAC-associated ICH (OAC-ICH) patients have worse outcomes as compared to ICH patients not on OAC, likely because of the associated larger stroke volumes, higher propensity to intraventricular hemorrhage, and a higher risk of rebleeding. Although current guidelines recommend that OAC should be reversed quickly, many health care systems have not developed a process for optimizing that aspect of care.
Methods: Through the IMPROVE Stroke Care Consortium, a group of nine Hub hospitals and their 57 regional community hospitals, a systems of care improvement project was implemented. Performance reviews identified best practices which were disseminated throughout all centers. We compared the median door-to-reversal (DTR) time before and after an institutional campaign to speed the process with a target time of 60 min.
Results: Over two years of the study, there were 6,699 ischemic strokes, 152 subarachnoid hemorrhages, and 889 intracerebral hemorrhages. During that time, 73 ICH patients received reversal agents emergently. The overall baseline median DTR time was 123 min (IQR 99, 361 minutes). By the end of the program, the median DTR time had trended down to 84 min (IQR 58.5, 151 min) which is a 31.7 % reduction of DTR from baseline, though times remained somewhat variable (p=0.08).
Conclusions: An integrated stroke systems of care approach was associated with a reduction in DTR times for patients presenting with acute ICH and concurrent use of anticoagulants despite lack of definitive guidelines around targets for OAC reversal times or operational guidance on protocols and agents.
Keywords: Anticoagulation; ICH; Outcomes; Quality.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Brad Kolls, MD, PhD reports financial support was provided by Medtronic Inc. Brad Kolls, MD, PhD reports financial support was provided by Daiichi Sankyo Inc. Brad Kolls, MD, PhD reports financial support was provided by Chiesi Pharmaceuticals Inc. Brad Kolls, MD, PhD reports financial support was provided by Pulsara. Brad Kolls, MD, PhD reports financial support was provided by Corazon. Brad Kolls, MD, PhD reports financial support was provided by Amwell. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
